Primary duodenal mucosa-associated lymphoid tissue (MALT) lymphoma – A rare presentation of gastric outlet obstruction

Tamar Tadmor MD1, Tova Rainis MD1, Jacob Bejar MD2, Dina Attias MD3, Alexandra Lavy MD1

1Gastroenterology Unit; 2Pathology Unit; 3Hematology Unit, Bnai-Zion Medical Center, Haifa, Israel

Correspondence: Dr Tova Rainis, Gastroenterology Unit, Bnai-Zion Medical Center, Golomb Street, Haifa, 31048 Israel.
Telephone 972-544-55-0002, fax 972-777-11-0311, e-mail tova@4utv.co.il

Received for publication March 14, 2006. Accepted July 17, 2006

Malignant lymphoma of mucosa-associated lymphoid tissue (MALT) has been recognized since the early 1980s as a distinct clinical and pathological entity that can arise in a variety of anatomical sites (1-3). The majority of these tumors arise in the stomach, with fewer than 30% arising in the small intestine (4,5). Primary duodenal MALT lymphoma is a very rare neoplasm (2-3,6-9). There are very few cases of duodenal MALT lymphoma reported in the literature. This is the third published case presenting clinically as a gastric outlet obstruction. The patient was successfully treated with a combination of chemotherapy and rituximab.

Key Words: Gastric outlet obstruction; MALT lymphoma; Rituximab

BRIEF COMMUNICATION

Primary duodenal mucosa-associated lymphoid tissue (MALT) lymphoma – A rare presentation of gastric outlet obstruction


Lymphome primitif duodénal du système lymphoïde des muqueuses : cas rare d’obstruction de l’orifice de sortie de l’estomac

Le lymphome malin du système lymphoïde des muqueuses (MALT) peut prendre naissance en divers points de l’organisme. Il se développe généralement dans l’estomac, et moins de 30 % des tumeurs naissent dans l’intestin grêle. Le lymphome primitif duodénal de type MALT s’observe très rarement, et la documentation ne fait état que de très peu de cas. Il s’agit, en fait, du troisième cas publié, se manifestant sous forme d’obstruction clinique de l’orifice de sortie de l’estomac. Le patient a été traité avec succès par la chimiothérapie et au rituximab

CASE PRESENTATION

A previously healthy 52-year-old woman was admitted with severe nausea, intractable vomiting and progressive weight loss of approximately 15 kg. Except for signs of cachexia, her physical examination was normal. Routine hematology and biochemistry tests were also normal. An abdominal computed tomography scan demonstrated a large mass, 7 cm × 5 cm × 5 cm, in the third part of the duodenum (Figure 1). Upper endoscopy demonstrated a normal gastric mucosa, and massive infiltration and narrowing of the duodenum (Figure 2). Histological examination of the stomach was normal and negative for Helicobacter pylori. Histology of the duodenal infiltration was compatible with MALT lymphoma: presence of lymphoepithelial lesions with a monoclonal population positive for CD19, CD20 and CD22, and negative for CD5, CD10, CD3 and cyclin D1 (Figure 3). Her bone marrow examination was also normal.

The patient was diagnosed as having stage EII MALT lymphoma. Chemotherapy with chlorambucil, prednisone and rituximab (monoclonal antibody-specific CD20) was initiated. The response was prompt, and shortly after the first cycle of therapy, the patient had no further obstructive symptoms and started gaining weight.

1Gastroenterology Unit; 2Pathology Unit; 3Hematology Unit, Bnai-Zion Medical Center, Haifa, Israel

Correspondence: Dr Tova Rainis, Gastroenterology Unit, Bnai-Zion Medical Center, Golomb Street, Haifa, 31048 Israel.
Telephone 972-544-55-0002, fax 972-777-11-0311, e-mail tova@4utv.co.il

Received for publication March 14, 2006. Accepted July 17, 2006
After one cycle of chemotherapy, the abdominal computed tomography scan showed 50% regression of the mass; a positron emission tomography–fluorodeoxyglucose scan after three months of therapy showed no evidence of the disease. Follow-up endoscopy six months after resolution of therapy was normal (Figure 4).

DISCUSSION
Primary lymphoma of the digestive tract accounts for 4.5% of all lymphomas (10,11). MALT lymphoma, first described by Isaacson and Wright (3), comprises 7% to 8% of all B cell lymphomas (12). MALT lymphoma is characterized by diffuse infiltration of the lamina propria by ‘centrocyte-like’ cells, and is associated with lymphoid follicles and lymphoepithelial lesions. The gastrointestinal tract is the most common site of MALT lymphomas, while the stomach is the most common location (4,5,10).

Primary duodenal MALT lymphoma represents a very rare neoplasm. Little is known of the presenting manifestations, natural course or treatment of duodenal MALT lymphoma, due to its rarity (2).

H pylori infection has been associated with gastric MALT lymphomas (13,14). The role of H pylori in duodenal MALT lymphoma is unclear. Therapy of H pylori infection has been correlated with tumour regression (6,15). Nagashima et al (6) reported regression of duodenal MALT lymphoma following eradication of H pylori. In our case, H pylori was negative.

Treatment of upper outlet obstruction due to low-grade MALT lymphoma has not yet been standardized. Most investigators recommend surgery, arguing that it is the best way to eradicate a localized and obstructing process (16). Being a mutilating procedure, surgery was considered too aggressive for our patient who presented with a low-grade MALT lymphoma.

Lepicard et al (17) reported four cases of duodenal MALT lymphoma treated with cyclophosphamide, which induced complete remission.

The use of rituximab in combination with chemotherapy has been evaluated as safe and active for the treatment of non-Hodgkin lymphoma, resulting in a significant increase in remission rates (18,19). Recently, Martinelli et al (20) confirmed that the use of rituximab is a very effective modality of treatment in gastric MALT lymphoma.

Our patient was treated with a combination of chlorambucil, prednisone and rituximab. She responded rapidly to the treatment and achieved complete remission. To the best of our knowledge, this is the first case of a duodenal MALT lymphoma treated successfully with rituximab in combination with chemotherapy.

CONCLUSION
MALT lymphoma of the duodenum is poorly characterized due to its rarity, and optimal treatment has not been elucidated.
The prognosis of duodenal low-grade MALT lymphoma is relatively good, and prolonged survival is possible with chemotherapy. The combination therapy of chlorambucil, prednisone and rituximab was well tolerated, active in inducing complete remission and avoiding mutilating surgery. The addition of rituximab to conventional chemotherapy may contribute to the significant positive response and length of remission. Further studies evaluating the use of rituximab alone or in combination with chemotherapy are warranted to define the best modality of treatment.

REFERENCES
Submit your manuscripts at http://www.hindawi.com